T cell subtype profiling measures exhaustion and predicts anti-PD-1 response
Open Access
- 25 January 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-16
Abstract
Anti-PD-1 therapy can provide long, durable benefit to a fraction of patients. The on-label PD-L1 test, however, does not accurately predict response. To build a better biomarker, we created a method called T Cell Subtype Profiling (TCSP) that characterizes the abundance of T cell subtypes (TCSs) in FFPE specimens using five RNA models. These TCS RNA models are created using functional methods, and robustly discriminate between naïve, activated, exhausted, effector memory, and central memory TCSs, without the reliance on non-specific, classical markers. TCSP is analytically valid and corroborates associations between TCSs and clinical outcomes. Multianalyte biomarkers based on TCS estimates predicted response to anti-PD-1 therapy in three different cancers and outperformed the indicated PD-L1 test, as well as Tumor Mutational Burden. Given the utility of TCSP, we investigated the abundance of TCSs in TCGA cancers and created a portal to enable researchers to discover other TCSP-based biomarkers.Keywords
Funding Information
- Cofactor Genomics
This publication has 93 references indexed in Scilit:
- A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyInternational Journal of Cancer, 2013
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivityNature, 2012
- T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elementsNature Communications, 2012
- The stromal cell antigen CD248 (endosialin) is expressed on naive CD8+ human T cells and regulates proliferationImmunology, 2011
- The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cellsNature Communications, 2011
- T Cell ActivationAnnual Review of Immunology, 2009
- CXCR4–CCR5: A couple modulating T cell functionsProceedings of the National Academy of Sciences, 2008
- The Biology of Interleukin-2Annual Review of Immunology, 2008
- A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast CancerNew England Journal of Medicine, 2004
- Lymphocyte‐activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytesEuropean Journal of Immunology, 1994